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HIV-1 compartmentalization in the CNS has been demonstrated for gag, pol, and env genes. However, little is known about tissue
compartmentalization of nef genes and their functional characteristics in brain. We have cloned 97 nef genes and characterized 10 Nef proteins
from autopsy brain and lymphoid tissues from 2 patients with AIDS and HIV-1-associated dementia. Distinct compartmentalization of brain
versus lymphoid nef genes was demonstrated within each patient. CD4 and MHC-I downregulation were conserved in all tissue-derived Nefs.
However, MHC-I downregulation by brain-derived Nefs was weaker than downregulation by lymphoid-derived Nefs. The motifs KEEE- or
EKEE- at the PACS-1 binding site represented brain-specific signature patterns in these 2 patients and contributed to the reduced MHC-I
downregulation activity of brain-derived Nefs from these patients. Pak2 association was highly variable in Nefs from both patients. Three of 10
tissue-derived Nefs coimmunoprecipitated activated Pak2, with strong association demonstrated for only 2 Nefs. The ability of Nef to associate
with activated Pak2 did not correlate with brain or lymphoid tissue origin. Nef genes from viruses isolated from brain by coculture with PBMC
were not closely related to sequences amplified directly from brain tissue, suggesting that viral selection or adaptation occurred during coculture.
This study of tissue-derived HIV-1 Nefs demonstrates that CD4 and MHC-I downregulation are highly conserved Nef functions, while Pak2
association is variable in late stage AIDS patients.
© 2006 Elsevier Inc. All rights reserved.Keywords: Human Immunodeficiency Virus type 1 (HIV-1); Nef; Brain; Lymph node; CD4; MHC-I; Pak2Introduction
The Nef protein of human and simian immunodeficiency
viruses (HIV-1, HIV-2 and SIV) is an important determinant of
progression to AIDS. Nef is required for maintenance of high
viral load and disease induction in SIV-infected rhesus monkeys
(Du et al., 1995; Kestler et al., 1991). Furthermore, expression of
the HIV-1 nef gene in transgenic mice produces AIDS-like
disease (Hanna et al., 1998; Skowronski et al., 1993). Nef-
defective HIV-1 has been associated with long-term non-
progression in infected individuals (Dyer et al., 1999; Kirchhoff
et al., 1995; Learmont et al., 1992). These findings suggest that
Nef is important for viral replication and pathogenicity in vivo.⁎ Corresponding author. Dana-Farber Cancer Institute, JFB 816, 44 Binney
St., Boston, MA 02115, USA. Fax: +1 617 632 3113.
E-mail address: dana_gabuzda@dfci.harvard.edu (D. Gabuzda).
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doi:10.1016/j.virol.2006.07.053HIV-1 Nef is a 27 kDa membrane-associated cytoplasmic
protein expressed during early stages of viral replication. Well-
studied functions of Nef include downregulation of CD4 and
MHC-I, enhancement of viral infectivity, and modulation of
cellular signaling pathways (reviewed in (Arold and Baur,
2001; Bour and Strebel, 2000; Fackler and Baur, 2002; Geyer et
al., 2001; Wei et al., 2003)). Nef downregulates CD4 by linking
cell surface CD4 to the adaptor protein complex of clathrin-
coated pits (Bresnahan et al., 1998; Greenberg et al., 1998a)
and transferring CD4 to COP-I for transport to lysosomes
(Piguet et al., 1999a). Downregulation of cell surface CD4
enhances HIV-1 replication and infectivity, virion production
and release, and prevents superinfection of infected cells
(reviewed in (Harris, 1999; Piguet et al., 1999b; Lama, 2003)).
MHC-I downregulation is achieved by targeting of MHC-I to
the endosome-to-Golgi sorting pathway governed by PACS-1
(phospho-furin acidic cluster sorting protein-1) (Doms and
120 K. Agopian et al. / Virology 358 (2007) 119–135Trono, 2000). Nef motifs critical for MHC-I downregulation
are the acidic EEEE62–65 motif, which binds PACS-1 (Piguet et
al., 2000), and the proline-rich SH3-binding domain (PxxP
domain) (Blagoveshchenskaya et al., 2002; Greenberg et al.,
1998b; Mangasarian et al., 1999). MHC-I downregulation may
be important for protection of infected cells against lysis
mediated by HIV-I-specific cytotoxic T lymphocytes in vivo
(Collins et al., 1998; Swigut et al., 2004; Tomiyama et al.,
2002; Yang et al., 2002). The mechanism by which Nef
enhances viral infectivity is still controversial.
Nef expression enhances HIV-1 replication when resting
peripheral blood mononuclear cells (PBMC) are infected and
subsequently stimulated (Miller et al., 1995; Spina et al., 1994),
most likely by activation of resting T cells through modulation
of cellular signaling pathways (Alexander et al., 1997; Baur et
al., 1994; Du et al., 1995; Schrager and Marsh, 1999; Simmons
et al., 2001; Wang et al., 2000; Wu and Marsh, 2001). In vivo,
the SIVmac239 nef gene enhances productive infection of
resting memory CD4+ T cells in the paracortical regions of
lymph nodes, thereby increasing viral replication and patho-
genicity (Sugimoto et al., 2003). The interaction between Nef
and p21-activated kinase 2 (Pak2), a cellular serine/threonine
kinase, has been proposed to play an important role in T cell
activation and AIDS progression in vivo (Arora et al., 2000; Lu
et al., 1996; Nunn and Marsh, 1996; Renkema et al., 1999;
Renkema et al., 2001; Sawai et al., 1996; Wei et al., 2005; Wolf
et al., 2001). Pak2 is involved in the regulation of several
cellular processes including cytoskeleton rearrangement, cell
morphology, motility, apoptosis and gene transcription and is
activated in response to a variety of cellular stresses (reviewed
in (Bagrodia and Cerione, 1999; Daniels and Bokoch, 1999)).
Nef–Pak2 association has also been demonstrated in primary
macrophages (Brown et al., 2004). The PxxP domain of Nef,
which is required for interaction with the SH3 domains of Src
tyrosine kinases and other signaling molecules, is required for
Pak2 activation (Khan et al., 1998; Manninen et al., 1998;
Wiskerchen and Cheng-Mayer, 1996). A cluster of residues on
the surface of the Nef core domain near F191 and H89 is also
critical for association with activated Pak2 (Agopian et al.,
2006; Foster et al., 2001; O'Neill et al., 2006), and may form
part of a unique binding surface specifically involved in Nef–
Pak2 association.
In addition to enhancing T cell activation, Nef also activates
signaling pathways in monocyte-derived macrophages. Macro-
phages play an important role in HIV-1 transmission and AIDS
pathogenesis, and are the primary cellular reservoir for HIV-1
infection in the CNS (Dunfee et al., 2006; Gonzalez-Scarano
and Martin-Garcia, 2005; Verani et al., 2005). HIV-1-infected
macrophages release inflammatory cytokines including MIP-
1α/CCL3, MIP-1β/CCL4, and other factors (e.g., IL-16 and
soluble forms of CD23 and ICAM-1) that contribute to
leukocyte recruitment and activation in a Nef-dependent
manner (Olivetta et al., 2003; Swingler et al., 1999, 2003;
Zhao et al., 2004). The PxxP domain and motifs involved in
CD4 downregulation in Nef are important for efficient viral
replication in macrophages (Brown et al., 2004). Nef-expres-
sing macrophages transplanted into the brain of rats inducemonocyte/macrophage recruitment, TNF-α expression, astro-
gliosis, and cognitive defects (Mordelet et al., 2004). Further-
more, SCID/NOD mice injected with Nef-expressing viral
vectors exhibited evidence of neuronal injury and neurological
disease (vanMarle et al., 2004). HIV-1-infected and/or activated
macrophages release soluble neurotoxic factors that induce
neuronal injury and neurocognitive impairment (Gonzalez-
Scarano and Martin-Garcia, 2005; Kaul et al., 2005). Nef may
regulate production of some of these neurotoxic factors by
stimulating macrophage activation (Mahlknecht et al., 2000;
Olivetta et al., 2005; Vilhardt et al., 2002).
HIV-1 enters the CNS in the early stages of infection by
trafficking across the blood–brain barrier within infected
monocytes and possibly lymphocytes (reviewed in (Williams
and Hickey, 2002; Dunfee et al., 2006)). However, productive
infection of macrophages and microglia is typically detected
only after progression to AIDS. Genetic evolution of HIV-1
within the brain is distinct from that in lymphoid tissues and
other organs (Chang et al., 1998; Donaldson et al., 1994;
Gartner et al., 1997; Gorry et al., 2001; Hughes et al., 1997;
Korber et al., 1994; Shapshak et al., 1999; van't Wout et al.,
1998; Wong et al., 1997). Previous studies demonstrated CNS
compartmentalization of the HIV-1 gag, pol, and env genes.
Only one previous study analyzed the genetic compartmenta-
lization of full-length nef genes in the CNS (van Marle et al.,
2004). This study also found that 3 brain-derived nef genes
differentially induced pro-inflammatory gene expression in
astrocytes, indicating that Nef sequence variability could affect
pathogenesis. However, little is known about functional
differences of Nefs from brain versus Nefs from other tissues.
Nefs in brain may be functionally divergent from those in blood
or lymphoid tissues as a consequence of adaptation to different
target cell populations and reduced immune surveillance. In
particular, low CD4 expression on macrophages/microglia and
reduced CTL surveillance in the brain could result in reduced
selection pressure to maintain strong CD4 or MHC-I down-
regulation activity, respectively.
To investigate genetic and functional characteristics of Nefs
in brain versus lymphoid tissues, full-length nef genes were
amplified from the genomic DNA of autopsy brain and
lymphoid tissues from 2 patients with late stage AIDS and
HIV-1-associated dementia (HAD). Distinct compartmentaliza-
tion of brain versus lymphoid nef sequences was demonstrated
within each patient. CD4 and MHC-I downregulation activities
were highly conserved among primary Nefs. However, MHC-I
downregulation by brain-derived Nefs was weaker than down-
regulation by lymphoid-derived Nefs. The motifs EKEE65 or
KEEE65 in the PACS-1 binding site were identified as brain-
specific signature patterns in both patients, whereas most
lymphoid Nefs had the motif EEEEE65. Mutagenesis demon-
strated that Nefs with EKEE65 or KEEE65 had a reduced
capacity to downregulate MHC-I Nefs with EEEE65. Higher
frequencies of EKEE65 or KEEE65 motifs and reduced capacity
to downregulate MHC-I in brain-derived Nefs from these 2
AIDS patients may reflect reduced immune selection pressures
in the CNS compared to non-CNS tissues. Of 10 brain- and
lymphoid tissue-derived Nefs, only 3 associated with activated
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brain or lymphoid tissue origin. These findings indicate that
CD4 and MHC-I downregulation are conserved in primary Nef
alleles derived from brain and lymphoid tissues from late stage
AIDS patients, while Pak2 activation is highly variable.
Results
Amplification of nef alleles from brain and lymphoid tissues
and brain- and lymph node-derived viral isolates
To compare genetic and functional characteristics of Nef
sequences from brain versus lymphoid tissues, we amplified nef
genes from the genomic DNA of autopsy brain and lymph node
tissues of 2 patients (MACS2 andMACS3) with late stage AIDS
and HIV-1-associated dementia (Gorry et al., 2001). Nef genes
were also amplified from the genomic DNA of spleen of patient
MACS2. Phylogenetic analysis showed that sequences from
both bulk and limiting dilution PCRs were well interleaved and
did not show evidence of amplification bias (data not shown). To
reduce potential effects of primer bias, 2 different primer sets
were used in limiting dilution PCR reactions. Although some
sequences were more commonly amplified by one or the other
primer set, both primer sets amplified at least one nef sequence
from every major branch of the phylogenetic trees (data not
shown). A total of 51 nef sequences were amplified directly from
MACS2 tissue (18 from brain, 22 from lymph node, and 11 from
spleen) and 46 from MACS3 tissue (12 from brain, and 34 from
lymph node). All nef sequences amplified directly fromMACS2
and MACS3 tissues encoded full-length open reading frames.
In addition to amplifying nef genes directly from the tissue
samples as discussed above, we also amplified nef genes from
viral isolates obtained from coculture of PBMC with the same
tissues. These isolates, MACS2-br, MACS2-LN, MACS3-br
andMACS3-LN, were described previously (Gorry et al., 2001).
For each viral isolate, we sequenced the bulk PCR product and 3
to 7 nef genes amplified from genomic DNA isolated from
PBMC on day 7 post-infection with virus stock. Within each
viral isolate, Nef clones were highly similar (98.3%–100% Nef
predicted amino acid identity). All nef genes from viral isolate
MACS2-br, including representative Nef clone 4G, contain an
early frameshift that introduced a stop codon after only 61 amino
acids. Clone MACS2-br-4G, could not be detected by Western
blot and was non-functional in assays for CD4 and MHC-I
downregulation and Pak2 activation (data not shown). Repre-
sentative Nef clones matching the consensus sequence of each of
the other viral isolates were chosen for further functional
analysis. Sequences and functional analyses of representative
viral isolate clones MACS2-LN-5C, MACS3-br-6I, and
MACS3-LN-7D have been published (Agopian et al., 2006).
Nef sequences from viral isolates derived from brain-PBMC
co-cultures are not representative of those in brain tissue
To determine whether coculture of brain tissue with PBMC
resulted in viral isolates representative of virus in the brain in
vivo, we used phylogenetic analysis to compare the nucleotidesequences of nef genes from PBMC/brain coculture-derived
viral isolates with sequences of nefs amplified directly from the
brain tissues. We found that nef sequences amplified from viral
isolates derived by brain-PBMC coculture were not representa-
tive of nef sequences in brain tissue. Even after repair of the
frameshift, the nucleotide sequence of nef clone 4G from viral
isolate MACS2-br (shown in pink in Fig. 1A) is highly
divergent from all other MACS2 sequences, including
sequences amplified directly from the brain of MACS2. The
sequence of nef clone 6I from viral isolate MACS3-Br is closely
related to nef sequences from lymph node tissue and is highly
divergent from nef sequences amplified directly from MACS3
brain. In contrast, the sequences of nef clones 5C and 7D from
viral isolates MACS2-LN and MACS3-LN were closely related
to nef sequences amplified directly from the DNA of MACS2 or
MACS3 lymph node tissue. Together, these data indicate that
nef sequences from primary viruses isolated by brain-PBMC
coculture are not necessarily representative of nef sequences in
the brain and suggest that viral selection or adaptation to PBMC
may have occurred during brain coculture.
Nef sequences in brain versus lymphoid tissue are
compartmentalized
Phylogenetic analysis revealed distinct compartmentaliza-
tion of tissue-derived brain versus lymphoid nef sequences
within each patient (Fig. 1). Nef sequences amplified directly
from 2 different sections of MACS2 frontal lobe tissue showed
very little sequence diversity (Fig. 1A). The low amount of
MACS2 brain nef sequence diversity is consistent with the low
HIV-1 copy numbers in these MACS2 brain tissue samples. Nef
sequences from MACS2 lymph node and spleen were more
diverse and were well interleaved, indicating a lack of compart-
mentalization between these 2 lymphoid tissues. Thus, in
patient MACS2, nef sequences are compartmentalized between
brain and lymphoid tissues. In patient MACS3, 8 nef sequences
amplified directly from brain were highly divergent from
sequences amplified from lymph node tissue (Fig. 1B). These
sequences comprise a branch of the MACS3 phylogenetic tree
that is represented solely by nef sequences from brain tissue.
Therefore we designated these 8 sequences as ‘true’ or ‘unique’
brain Nefs. Four nef sequences amplified from MACS3 brain
tissue were identical or nearly identical to sequences amplified
from lymph node. Thus, patient MACS3 demonstrates both
compartmentalized brain nef sequences and nef sequences
shared by lymph node and brain. Together, phylogenetic data
from both late-stage AIDS patients MACS2 and MACS3
demonstrate compartmentalization of nef sequences in the brain
versus lymphoid tissues.
Conservation of motifs in representative tissue-derived nef
sequences
To test for functional differences between Nef sequences
from brain versus lymphoid tissue, 2 to 3 representative nef
sequences from each tissue were selected (circled in Fig. 1).
These Nefs were chosen so that all major branches of each
Fig. 1. Phylogenetic analysis of full-length HIV-1 nef nucleotide sequences from autopsy tissue samples and viral isolates from AIDS patients MACS2 (A) and
MACS3 (B). Nef sequences amplified directly from frontal lobe, spleen, and lymph node tissues are color-coded pink, green and black, respectively. Nef sequences
from brain and lymph node viral isolates obtained by PBMC co-culture are color-coded orange and blue, respectively. *MACS2-br isolate clones all contained a
frameshift resulting in truncation after 60 amino acids and undetectable protein expression. To determine the phylogenetic relationship of viral isolate MACS2-br to
other MACS2 sequences, the entire region of the MACS2-br 4G sequence corresponding to the intact nef ORF was used in the alignment. Numbers associated with
each branch are bootstrap values, which represent the number of trees, out of 1000 replicates performed, in which the same branching order was found. Only values
above 700 for the major branches are shown. Branch lengths are proportional to amount of sequence divergence. Scale bars indicate 1% sequence divergence. An
ellipse indicates tissue-derived clones used in functional analyses. Isolate-derived clones analyzed previously (Agopian et al., 2006) are indicated by a rectangle.
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sequence alignment of these representative Nefs. Well-
conserved motifs in these Nefs include the myristoylation
signal (Geyer et al., 2001), the PxxP SH3-binding region
(Saksela et al., 1995), the putative CD4 binding site (Grzesiek
et al., 1996), and motifs in the flexible loop proposed to be
important for association with the endocytic machinery
including β-COP (Piguet et al., 1999a), adaptor proteins AP-
1/2/3 (Bresnahan et al., 1998; Craig et al., 1998; Greenberg et
al., 1998a) and vacuolar ATPase (Lu et al., 1998). More
variable motifs in our primary Nefs are the PACS-1 binding
motif (Piguet et al., 2000), residues 85, 89, 187, 188, and 191
important for Pak2 association (Agopian et al., 2006; O'Neill et
al., 2006), and the FPD121 motif implicated in thioesterase
binding (Cohen et al., 2000). Analysis of Nef expression in
293 T cells by Western blotting suggests that except for 16N,
these Nef proteins are expressed at levels similar to those of
control Nef proteins SF2 and NL4-3 (see Figs. 3B, 4B, and 5AFig. 2. Amino acid alignment of primary HIV-1 Nef clones with the Clade B consens
2000), and residues 85, 89, 187, 188 and 191, important for Pak2 association (Agopi
proposed Nef domains, including the myristoylation signal (Geyer et al., 2001), the
(Grzesiek et al., 1996), and the putative binding sites for thioesterase (Cohen et al.,
adaptor proteins AP-1/2/3 (Bresnahan et al., 1998; Craig et al., 1998; Greenberg et al
the LANL sequence database (August 2004).and B). Nef 16N contains the variation T80I, which disrupts a
consensus phosphate acceptor target for protein kinase C
(Shugars et al., 1993). Mutation of this highly conserved
threonine has been shown to reduce protein stability (Aiken et
al., 1996). Although Western blotting with three different
polyclonal sera suggests that 16N is expressed at lower levels
compared to the other Nef alleles, we cannot rule out the
possibility that 16N is well expressed but poorly recognized by
these sera. All five MACS3 brain Nef sequences closely related
to 16N carry this T80I variation.
CD4 downregulation is highly conserved
To examine the ability of brain and lymphoid Nef proteins to
downregulate CD4, we co-transfected Nef and GFP plasmids
into HIJ cells (MAGI cells expressing high levels of CD4) and
analyzed cells for surface expression of CD4 by flow cytometry
(Fig. 3). The LL164AA mutation, previously shown to abolishus. The PACS-1 binding site, important for MHC downregulation (Piguet et al.,
an et al., 2006; O'Neill et al., 2006) are shaded. Bars mark the locations of other
PxxP SH3-binding region (Saksela et al., 1995), the putative CD4 binding site
2000), and the endocytic machinery components β-COP (Piguet et al., 1999a),
., 1998a) and vacuolar ATPase (Lu et al., 1998). The Clade B consensus is from
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Nef and was included as a negative control (Bresnahan et al.,
1998; Craig et al., 1998; Greenberg et al., 1998a). We also
included the EEEE65/AAAA (E4A) mutant of NL4-3 Nef which
is defective for MHC-I downregulation but efficiently down-
regulates CD4 (Piguet et al., 2000). CD4 downregulation
activity was highly conserved among primary Nefs, with all
10 clones showing at least some CD4 downregulation activity.
Furthermore, 9 out of 10 primary clones downregulated CD4 at
least as strongly as NL4-3 Nef. Six of these clones down-
regulated CD4 more strongly than NL4-3 Nef (p<0.05 by
Student's two-tailed t test). Only one primary clone, MACS3
brain-derived Nef clone 16P, had weaker CD4 downregulation
activity than NL4-3 Nef (p<0.05). Nef 16P also had less thanFig. 3. Downregulation of cell surface CD4 is conserved in primary Nef alleles from
surface CD4 in HIJ cells co-transfected with pCDNA3-EGFP and either pCR3.1 (Ve
from the geometric mean PE fluorescence in GFP-positive cells as described in Mate
Averages are from 3 independent experiments. Error bars represent standard deviation
by Western blot. Lysates were split and identical membranes were blotted in paralle
Primary FACS data for flow cytometric analysis of cell surface CD4 in transfected HIJ
representative of three independent experiments.half the activity of the other primary Nef clones (p<0.001).
MACS3 brain-derived Nef clone 16N strongly downregulated
CD4, despite an apparent lower expression level suggested by
Western blot (Fig. 3B). Moderately lower levels of Nef 16Nmay
be sufficient for strong CD4 downregulation activity, since this
function is induced even at lower concentrations of Nef (Fig. 3C
and (Liu et al., 2001)). Alternatively, Nef 16N may be expressed
at levels comparable to those of the other Nef alleles but poorly
recognized by the polyclonal sera. Overall, there was no
significant difference in CD4 downregulation activity between
brain and lymphoid Nef clones. Together, these data demonstrate
that CD4 downregulation is a highly conserved phenotype of
primary Nef proteins from brain and lymphoid tissues of late
stage AIDS patients.brain and lymphoid tissues. (A) Quantitation of flow cytometric analysis of cell
ctor) or pCR3.1-Nef plasmids as indicated. Relative surface CD4 was calculated
rials and methods and is shown relative to GFP-positive vector-transfected cells.
s. (B) Nef expression in HIJ cells assayed for CD4 downregulation is confirmed
l with either rabbit anti-Nef #188 (raised to Bru) or rabbit anti-Nef #2949. (C)
cells. Vertical lines indicate the threshold for GFP positive cells. Data shown are
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Nefs have reduced MHC-I downregulation
To examine the ability of brain and lymphoid Nefs to
downregulate MHC-I, we co-transfected Nef and GFP plasmids
into Jurkat-T-Antigen cells and analyzed cells for surface ex-
pression of HLA-ABC by flow cytometry. MHC-I downregula-
tion by Nef is generally less efficient than CD4 downregulation,
with higher Nef expression levels required to induce MHC-I
downregulation. Therefore, we only analyzed high-expressing
cells, marked by high GFP levels. As a negative control, we
included the EEEE65/AAAA (E4A) mutant of NL4-3, which hasFig. 4. Downregulation of cell surface MHC-I by primary Nef proteins from brain an
HLA-ABC in Jurkat T-Antigen cells co-transfected with pCDNA3-EGFP and either
ABC was calculated from the geometric mean PE fluorescence in GFP-high-expressin
vector-transfected cells. Averages are from 2 to 5 independent experiments. Error bars
for MHC-I downregulation assays confirmed by Western blot. Lysates were split an
(raised to Bru) or rabbit anti-Nef #2949. (C) Primary FACS data for flow cytometric a
indicate the thresholds for GFP-negative, GFP-low and GFP-high expressing cells.been shown to abolish MHC-I downregulation (Piguet et al.,
2000). All primary Nef clones downregulated MHC-I (Fig. 4).
However, as a group, brain-derived Nef clones (14A, 14E, 16N,
16P) induced less MHC-I downregulation than lymphoid-
derived Nef clones (15A, 15F, 25E, 17A, 17B, 17F) (Wilcoxon
rank sum test, two-sided p value=0.01). Furthermore, all
lymphoid-derived Nef clones downregulated MHC-I more
strongly than did NL4-3 Nef (p values<0.05 by Student's t
test for each Nef versus NL4-3). MACS2 brain Nef alleles were
expressed at levels comparable toMACS2 lymphoid Nef alleles,
suggesting that their reduced capacity to downregulateMHC-I is
due to a specific functional defect (Fig. 4B). However, MACS3d lymphoid tissues. (A) Quantitation of flow cytometric analysis of cell surface
pCR3.1 (Vector) or pCR3.1-Nef plasmids as indicated. Relative surface HLA-
g cells as described in Materials and methods and is shown relative to GFP-high
represent standard deviations. (B) Nef expression in Jurkat T-Antigen cells used
d identical membranes were blotted in parallel with either rabbit anti-Nef #188
nalysis of cell surface MHC-I in transfected Jurkat T-Antigen cells. Vertical lines
Data shown are representative of two to five independent experiments.
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lymphoid Nef expression levels (Fig. 4B and data not shown).
Therefore, it is unclear whether the reduced ability of MACS3
brain Nef clones to downregulate MHC-I is due to a specific
functional defect or simply to lower expression levels. Never-
theless, these data demonstrate that while MHC-I downregula-
tion is conserved in primary brain- and lymphoid-derived Nef
clones, brain-derived Nefs are reduced in their ability to down-
regulate MHC-I relative to lymphoid Nefs in these 2 late stage
AIDS patients.
Motifs KEEE- or EKEE- at the PACS-1 binding site represent
brain-specific signature patterns and contribute to reduced
MHC-I downregulation
Subtle differences in the PACS-1 binding site, which is
important for MHC-I downregulation (Blagoveshchenskaya et
al., 2002; Piguet et al., 2000), were observed in brain- versus
lymphoid-derived Nef clones (Fig. 2). Comparison of allFig. 5. Association of primary HIV-1 Nef proteins with activated Pak2 is highly varia
the indicated Nef proteins were immunoprecipitated with sheep-anti-Nef (raised to SF
SF2 Nef and MACS2 5C Nef, previously demonstrated to strongly activate Pak2 (
arrowhead indicates the 62 kDa band corresponding to Pak2. Whole cell lysates u
antibody #2949 or sheep anti-Nef (bottom panels). (B) 293T cells transiently expressin
Nef and Western blotted with rabbit anti-Nef #2949 to confirm efficient Nef immuno
Nef antibody #2949 (middle panel) or anti-GFP (bottom panel).sequences across the data set from both patients using Viral
Epidemiology Signature Pattern Analysis (VESPA) identified
only one brain-specific pattern in Nef clones from both patients.
A high frequency of Nef clones unique to brain had only 3
glutamic acids (EKEE-65 or KEEE-65) in the PACS-1 binding
site (Table 1). In contrast, the majority of Nef sequences from
lymphoid tissue had 5 glutamic acids (EEEEE65). Representative
of this difference, brain-derived Nef clones 14A, 14E and 16N
have either the KEEE- or EKEE- motifs in their PACS-1 binding
site, while 5 of 6 representative lymphoid Nef clones have 5
glutamic acids. The KEEE- or EKEE- sequences found in these
brain-derived Nef clones are rare among Clade BNef sequences,
with only 0.88% or 0.44% of Nef sequences in the LANL
database containing these sequences, respectively (Table 2).
Therefore, we hypothesized that the KEEE- or EKEE- motifs
represent a rare brain-specific signature pattern in these 2
patients that results in reduced ability to downregulate MHC-I.
To determine if the EKEE or KEEE motifs influence the
ability of the primary Nef clones to downregulate MHC-I,ble. (A) In vitro kinase assay (IVKA). 293T cells transiently expressing GFP and
2 Nef) and assayed by IVKA (top panel) as described in Materials and methods.
Arora et al., 2000; Agopian et al., 2006), are included as positive controls. An
sed for IVKA immunoprecipitations were immunoblotted with rabbit-anti-Nef
g GFP and the indicated Nef proteins were immunoprecipitated with sheep-anti-
precipitation (top panel). Input whole cell lysates were immunoblotted with anti-
Table 2
PACS-1 binding site motifs in clade B Nef sequences a
Nef 62–65 HIV Clade B (n=455)
EEEE- 62.7%
EDEE- 12.1%
KEEE- 0.88%
EKEE- 0.44%
EEEEE 9.27%
Other b 14.61%
a Clade B Nef sequences deposited in the LANL database.
b Includes approximately 23 low-frequency variants.
Table 1
Frequency of motifs at PACS-1 binding site in tissue-derived Nef sequences a
Patient Brain Lymphoid
MACS2 18/18 KEEE-(14A, 14E) 1/24 EEEEK
23/24 EEEEE (15A, 15F, 25E)
MACS3 6/8 EKEE-(16N) 19/34 EQEEE (17F)
2/8 EEEE-(16P) 15/34 EEEEE (17A, 17B)
Total 18/26 KEEE- 38/58 EEEEE
6/26 EKEE- 19/58 EQEEE
2/26 EEEE- 1/58 EEEEK
a Nef sequences unique to brain were compared to sequences from lymph
node and spleen. VESPA analysis indicated signature sequences at positions 62–
66 which distinguished brain-derived Nef sequences from lymphoid-derived
Nef sequences. Sequence frequencies in each tissue are shown. Representative
Nef clones used in functional assays are in parentheses.
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16N backgrounds to restore the more common EEEE motif to
these Nef proteins. Additionally, a fifth glutamic acid was
inserted into the PACS-1 binding sites of these Nef clones to
determine if an increased number of glutamic acids in the
PACS-1 binding site enhances MHC-I downregulation activity.
Nef mutant 14E-EEEE downregulated MHC-I more strongly
than Nef 14E (p<0.01 by Student's t test) and Nef 14E-EEEEE
was even more potent relative to parental MACS2FL-14E
(p<0.001) (Fig. 4A). In fact, there was no significant difference
in downregulation of MHC-I by 14E-EEEEE versus MACS2
lymphoid-derived Nef clones 15A and 15F, which contain the
EEEEE motif in their PACS-1 binding sites. Nef 16N-EEEE
also downregulated MHC-I more strongly than did the parental
clone 16N. However, Western blot analyses suggest that this
Nef is expressed at higher levels than clone 16N. Therefore, it is
not possible to conclude whether the mutation at the PACS-1
binding site specifically increased MHC-I downregulation
activity. However, Nef 16N-EEEEE appeared to be expressed
at levels similar to those of 16N, but downregulated MHC-I
more strongly than 16N (p<0.01). Since the expression of 16N
appears to be low, it is difficult to compare its MHC-I
downregulation activity directly to that of the MACS3
lymphoid-derived Nef clones. Nevertheless, the 14E and 16N
mutagenesis data support the hypothesis that 5 glutamic acids in
the PACS-1 binding site result in the strongest downregulation
of MHC-1, while the KEEE or EKEE motifs reduce MHC-I
downregulation relative to the more common EEEE motif.
Therefore, the reduced MHC-I downregulation activity of the
brain-derived Nef clones in these 2 patients is likely a
consequence of their KEEE or EKEE motifs and can be en-
hanced by mutation of these motifs to the more potent EEEE or
EEEEE motifs.
Pak2 association is variable, and does not correlate with brain
or lymphoid origin of Nef sequences
To determine whether association with activated Pak2 is
conserved in primary brain and lymphoid-derived Nef proteins,
representative Nef clones were tested for their ability to
immunoprecipitate activated Pak2 by in vitro kinase assay
(IVKA) (Fig. 5A). SF2 Nef and MACS2-LN isolate Nef clone5Cwere used as positive controls (Agopian et al., 2006; Foster et
al., 2001). 5C Nef associates with a very high amount of
activated Pak2, while SF2 Nef is commonly used as a positive
control for this assay (Arora et al., 2000; Foster et al., 2001; Luo
and Garcia, 1996; Sawai et al., 1994). Of 10 tissue-derived Nef
clones tested, 7 clones did not coimmunoprecipitate detectable
Pak2 activity (Fig. 5A). Two tissue-derived Nef clones
(MACS2LN-15A and MACS3FL-16P) coimmunoprecipitated
more activated Pak2 than did the positive control SF2 Nef. Nef
clone 16N coimmunoprecipitated a small amount of activated
Pak2. Although Western blots with three different polyclonal
antibodies suggest that Nef clone 16N has a lower expression
level relative to the other Nef clones (see Figs. 3B, 4B, and 5A),
lower expression alone cannot account entirely for the small
amount of activated Pak2 immunoprecipitated by Nef 16N. To
confirm that all Nef proteins were efficiently immunoprecipi-
tated, anti-Nef Western blots were performed on anti-Nef
immunoprecipitates (Fig. 5B). All Nef clones except 16N
appeared to be efficiently immunoprecipitated. Since 16N
appears to have a lower expression level than that of the other
Nef alleles and is poorly recognized by the rabbit polyclonal
antibody, it is likely that 16N was efficiently immunoprecipi-
tated but its detection by Western blot was limited by a lower
concentration of 16N in the cell lysate. Out of 10 tissue-derived
Nef clones, we consider 2 to strongly associate with activated
Pak2 and 1 to weakly associate with activated Pak2. Of MACS2
tissue-derived Nef clones, only 1 lymphoid-derived and no
brain-derived Nef associated with activated Pak2. For MACS3,
both brain-derived Nef clones but none of the lymphoid-derived
clones associated with activated Pak2. These results demonstrate
that the ability to coimmunoprecipitate activated Pak2 is not well
conserved in primary Nef alleles from late stage AIDS patients.
Furthermore, the ability of Nef sequences to associate with
activated Pak2 did not correlate with either brain or lymphoid
tissue origin in these 2 patients.
The ability of tissue-derived Nef clones to associate with
activated Pak2 appeared to segregate with distinct branches of
the phylogenetic trees (Fig. 6). MACS2 Nef alleles 15A and 5C
immunoprecipitated a very high amount of activated Pak2 and
share motif F89I187H188H191 at residues critical for Pak2
association (Fig. 2 and (Agopian et al., 2006)), while clones
14A, 14E, 15F and 25E differ at some or all of these residues.
Unlike most Clade B Nefs, all Nef clones from MACS2 have a
phenylalanine at position 85, which is also critical for Pak2
association (Agopian et al., 2006). It is possible that in the
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associate with activated Pak2. If so, we predict that all MACS2
Nef alleles with motif F89I187H188H191 (in black in Fig. 6A)
would associate with activated Pak2, while other Nefs that differ
at these residues (in blue in Fig. 6B) would be defective for this
function. In patientMACS3, Nef clones 17A, 17B, and 17F have
no variations in residues previously identified as specifically
critical for Pak2 activation (Fig. 2). However, these alleles, like
many Nef alleles from patient MACS3, have the variation F90L.Fig. 6. Phylogenetic analysis of HIV-1 Nef amino acid sequences from AIDS pat
F89I187H188H191 motif are colored black. Nef clones containing other motifs at the
consensus phenylalanine at residue 90 are colored black and Nef clones with a leuci
shown. Scale bars represent 1% amino acid sequence divergence. Ellipses or recta
association in this study or previously (Agopian et al., 2006).Residue 90 of Nef is a phenylalanine in the clade B consensus
sequence. F90 interacts with the RT loop of SH3 domains (Lee et
al., 1996; Lim et al., 1997) and mutation of this residue or its
corresponding residue in SIV, F122, reduced or abolished
association of Nef with Hck and NAK/Pak2 (Khan et al., 1998;
Manninen et al., 1998). Therefore, the F90L variation in most
MACS3 Nefs (shown in blue in Fig. 6B) would be expected to
abolish Pak2 association. Barring other deleterious mutations,
only the MACS3 alleles with F90 (shown in black in Fig. 6B)ients MACS2 (A) and MACS3 (B). (A) MACS2 Nef proteins containing the
se residues are colored blue. (B) MACS3 Nef proteins containing the Clade B
ne at position 90 are colored blue. Bootstrap values above 700 (out of 1000) are
ngles indicate clones analyzed for CD4 and MHC-I downregulation and Pak2
129K. Agopian et al. / Virology 358 (2007) 119–135have the potential for Pak2 association. Thus, about one-third of
all Nefs from patients MACS2 and MACS3 are predicted to
associate with activated Pak2 based on sequence analysis.
Discussion
This study provides evidence for distinct compartmentaliza-
tion of nef genes from brain and lymphoid tissues of 2 patients
with AIDS and HIV-1-associated dementia. CD4 downregula-
tion activity was highly conserved among primary Nefs from
brain and lymphoid tissues; 9 of 10 Nef clones downregulated
CD4 strongly, in most cases more strongly than NL4-3 Nef, and
one downregulated CD4 weakly. MHC-I downregulation was
also conserved in these primary Nef clones. However, MHC-I
downregulation by brain-derived Nefs was weaker than down-
regulation by lymphoid-derived Nefs. The motifs KEEE- or
EKEE- at the PACS-1 binding site represented brain-specific
signature patterns in these 2 patients that contributed to the
reduced MHC-I downregulation ability of brain-derived Nefs
that contained these motifs. In contrast to CD4 and MHC-I
downregulation, Pak2 associationwas not well conserved. Three
of 10 tissue-derived Nefs coimmunoprecipitated detectable acti-
vated Pak2, and only 2 of these were strongly associated with
Pak2. Thus, CD4 and MHC-I downregulation are highly con-
served Nef functions, while Pak2 association is variable in Nef
clones from these 2 late stage AIDS patients.
Nef genes from viruses isolated from brain by coculture with
PBMC were more closely related to sequences amplified from
lymphoid tissue than from brain tissue, suggesting that viral
selection or adaptation occurred during coculture. Thus, future
studies of brain-specific genes should avoid isolating virus by
co-culture with PBMC. Four brain-derived MACS3 sequences
were identical to sequences from lymph node. These nef
sequences could represent HIV-1 neuroinvasion during late
stage AIDS after the blood–brain barrier has been disrupted,
contamination by blood vessels that contain blood-derived or
lymphoid Nef sequences, or archived ancestral sequences. Two
main hypotheses have been proposed regarding the source of
HIV-1 divergence within the CNS (McCrossan et al., 2006): (1)
divergence is a result of early entry followed by isolation and
genetic divergence; and (2) HIV-1 in the brain is a subpopula-
tion of macrophage-tropic virus present in macrophages
throughout the body, representing a macrophage-specific rather
than brain-specific viral subpopulation. Thus, these 4 nef
sequences amplified from brain that are similar to lymphoid-
derived Nefs could represent archival HIV sequences in the
brain present prior to genetic divergence or sequences from
replicating macrophage-tropic subset of virus that is also present
in lymphoid tissues.
CD4 downregulation activity was highly conserved in brain
and lymphoid Nef alleles, consistent with previous reports that
found 75–100% conservation of CD4 downregulation activity
in Nefs from rapid progressors and late stage AIDS patients
(Casartelli et al., 2003; Michael et al., 1995; Ratner et al., 1996;
Tobiume et al., 2002). Brain-derived MACS3 Nef 16P was the
only Nef with reduced CD4 downregulation. In Nef 16P, the
WL58 CD4 binding site and the motifs in the flexible loop criticalfor association with the endocytic machinery are all conserved
(Geyer et al., 2001). However, 16P contains the variation P122S.
Mutation of proline122 dramatically affects both downregula-
tion of CD4 and association with thioesterase (Cohen et al.,
2000; Liu et al., 2000). Therefore, the P122S change may account
for the reduced CD4 downregulation activity of Nef 16P.
By increasing the efficiency of viral particle release and
subsequent engagement of CD4 receptors on target cells,
downregulation of cell surface CD4 is one mechanism through
which Nef enhances viral infectivity (Lama, 2003; Lama et al.,
1999; Ross et al., 1999). CD4 downregulation is the most
dramatic Nef function, and possibly the most important.
Therefore, it is not surprising that this function is so highly
conserved in our primary Nef alleles. It is important to note the
strong conservation of CD4 downregulation in the brain, where
target cells such as macrophages and microglia have very low
CD4 levels. Our data, together with previous reports showing
that even low levels of CD4, similar to those found in primary
macrophages, significantly reduce the infectivity of HIV
particles (Cortes et al., 2002) and that viruses expressing Nef
alleles defective in CD4 downregulation exhibit delayed
replication kinetics and reduced infectivity in primary macro-
phages (Brown et al., 2004) suggest that Nef-mediated CD4
downregulation is a critically important function in both high-
CD4-expressing lymphocytes and low-CD4-expressing macro-
phages. These data underscore the importance of CD4 down-
regulation in the HIV life cycle.
All tissue-derived Nef alleles downregulated MHC-I. This
finding is consistent with previous reports showing 90–100%
conservation of this activity in progressing and late stage AIDS
patients (Casartelli et al., 2003; Tobiume et al., 2002). The
preservation of MHC-I downregulation in Nefs from these late
stage AIDS patients suggests that MHC-I downregulation is an
important function in the life cycle of HIV-1. However, in the 2
AIDS patients studied here, MHC-I downregulation by brain-
derived Nefs was weaker than downregulation by lymphoid-
derived Nefs. Furthermore, we demonstrated that motifs KEEE-
or EKEE- at the PACS-1 binding site represented brain-specific
signature patterns in these patients. Mutational analysis
confirmed that KEEE-65 or EKEE-65 contributed to the reduced
MHC-I downregulation ability of brain-derived Nefs from
patients MACS2 andMACS3. To our knowledge, this is the first
report of a functional difference between brain- and lymphoid-
derived Nefs.
The motifs KEEE-65 or EKEE-65 are found in only 1.32% of
455 Clade B Nefs in the LANL database and only 1.2% of 1643
Clade B Nefs in the database of Foster and colleagues (O'Neill
et al., 2006). Since these rare motifs were found at a high
frequency in the brain but not lymphoid tissues of the 2 AIDS
patients studied here, we hypothesized that these motifs might
represent brain-specific signatures in some individuals with
AIDS. In one previous report, 5 Nef clones derived from in vitro
infection of PBMC with HIV-1 isolated from the cerebrospinal
fluid of an AIDS dementia patient were found to have the motif
KEEE (McPhee et al., 1998). In contrast, all 12 sequences
amplified directly from uncultured brain tissue by Saksena et al.
and the 2 sequences amplified directly from uncultured brain
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1992; Saksena et al., 1997). Furthermore, 10 of 11 sequences
amplified directly from brain by Van Marle et. al. contain EEEE
or EDEE motifs (van Marle et al., 2004). Therefore, EKEE and
KEEE are associated with brain-derived Nefs in only a subset of
AIDS patients. A search of the database of 1643 Nef alleles
(O'Neill et al., 2006) revealed that 6 of 11 Nef sequences with
motif KEEE were isolated from PBMC or plasma RNA
(Asamitsu et al., 1999; Fang et al., 1999, 2001; Hahn et al.,
2003; Kirchhoff et al., 1999), and 3 of 9 sequences with motif
EKEE were isolated from PBMC (Asamitsu et al., 1999), while
the source of the other 6 was not specified (Cho, and Ahn, direct
submission, 2005 and Ashton, L et al unpublished, 2002).
Therefore, the EKEE and KEEE motifs are not excluded from
blood or lymphoid tissues nor are they a common brain signature
pattern. Since immune surveillance is reduced in the CNS
compared to non-CNS tissues, the brain may be a more
permissive tissue site for maintenance of Nef alleles with weaker
MHC-I downregulation.
In contrast to CD4 and MHC-I downregulation, Pak2 asso-
ciation was not well conserved in primary Nef alleles from 2
late stage AIDS patients. Only 3 of 10 tissue-derived Nefs
immunoprecipitated Pak2. We found a higher frequency of Nef
alleles positive for Pak2 activation (5 of 7) in Nef alleles from
primary viral isolates UK1-Br, MACS1-Br, MACS1-Sp,
MACS2-LN (5C), MACS3-br (6I), MACS3-LN (7D) and
slow progressorΔ32-Blood [(Agopian et al., 2006; Gorry et al.,
2001) and unpublished data]. Other studies also found higher
rates of association with activated Pak2 among primary Nef
alleles. In one study, 3 of 5 subtype B Nefs were positive for
Pak2 activation and a second study found that 1 of 2 subtype B
and 5 of 5 subtype E HIV-1 Nefs activated Pak2 (Foster et al.,
2001; Huang et al., 1995; O'Neill et al., 2006). Furthermore, 5
of 5 Group O and N and 3 of 6 SIVcpz Nefs were strongly
positive for Pak2 activation (Kirchhoff et al., 2004). The
methods used by Kirchhoff et al appear to be more sensitive for
detecting Pak2 association, since NL4-3 Nef coimmunopreci-
pitates a stronger band of Pak2 activity in their assay compared
to ours (Arora et al., 2000; Luo and Garcia, 1996). Our IVKA
detects Nef association with endogenous Pak2, whereas the
IVKA used by Kirchhoff et. al. detects association with
exogenous Pak2 in cells cotransfected with activated
Cdc42V12 (Pulkkinen et al., 2004).
The significance of the low frequency of Pak2 association in
primary Nef alleles in our study remains unclear. Compilation of
results of previous studies of Pak2 association suggests a
frequency of 80% (16/20) positive in HIV-1 Nef alleles and
100% (7/7) positive in SIV Nef alleles (Foster et al., 2001;
Kirchhoff et al., 2004; Luo and Garcia, 1996; O'Neill et al.,
2006). An important distinction between our study and previous
studies is the number of independent nef alleles amplified by
limiting dilution from each patient and our selection, based on
phylogenetics, of representative alleles to be tested in functional
assays. Other studies that analyzed Nefs from several patients
typically selected only one or a few alleles representing each
patient. Further studies examining large numbers of Nef clones
from several patients are needed to determine the true proportionof Nef alleles that efficiently associate with and/or activate Pak2
in vivo.
If the true frequency of Nef alleles positive for Pak2
association in vivo is indeed low, then what is the significance
of Nef–Pak2 association during the course of HIV infection?
Evidence of compensation and co-variation between Nef
residues critical for association with Pak2 suggests that Nef-
mediated activation of Pak2 confers a selective advantage during
the course of HIV infection (Agopian et al., 2006; O'Neill et al.,
2006). Nef-mediated activation of Pak2 might be critical for
infection of particular cell types during a specific stage(s) of
infection. In the present study, tissue samples from patients
MACS2 and MACS3 were collected during autopsy and
therefore represent end-stage AIDS. If Pak2 activation is indeed
critical for enhancement of T cell activation, as previously
proposed (Fackler et al., 1999; Lu et al., 1996; Vilhardt et al.,
2002; Wei et al., 2005; Wolf et al., 2001), then this function
might be particularly important during transmission and/or early
stages of infection when resting T cells are important targets for
infection in genital mucosa and gut-associated lymphoid tissues
(Pope and Haase, 2003). Nef residues important for Pak2
activation are also targets for CTLs (Los Alamos National
Laboratories Database). Thus, the high level of variation at these
sites in MACS2 could also reflect CTL escape. Further studies
are needed to determine if the frequency of Nef alleles positive
for Pak2 activation differs between specific types of infected
cells or during the course of infection. The primary Nef alleles
described here will facilitate future studies to investigate the
importance of Nef–Pak2 association and other Nef functions for
HIV-1 replication and pathogenesis.
Materials and methods
Amplification of HIV-1 Nef alleles from autopsy tissue
Genomic DNA was extracted from autopsy samples of
uncultured brain, lymph node and spleen tissue from patients
MACS2 and MACS3 using the Gentra Puregene DNA Purifica-
tion kit (Gentra). PatientsMACS2 andMACS3were participants
in theChicagoComponent of theMulticenterAIDSCohort Study
who had late stage AIDS and HIV-1-associated dementia (Gorry
et al., 2001). Quantification of HIV-1 gag copy number by real-
time PCR was performed using the TaqMan Universal PCR
Master Mix (Applied Biosystems, Foster City, CA) and primers
CCR5-933R (5′-TGAAGATAAGCCTCACAGCCCT-3′),
CCR5-778F (5′-AGGTCTTCATTACACCTGCAGCTC-3′),
CCR5 probe (5′-CAGTCAGTATCAATTCTGGAAGAATT-
TCCAGACAT-3′), 793-gag F (5′-GGTGCGAGAGCGTCAG-
TATTAAG-3′), 911-gag R (5′-AGCTCCCTGCTTGCCCATA-
3′), and 835-gag probe (5′ TGGGAAAAAATTCGGTTAAG-
GCCAGGG-3′). Cycling conditions were 95 °C (15 min),
followed by 45 cycles of 95 °C (15 s), 60 °C (1 min), 25 °C
(2 min). Copies of HIV-1 gag per million cells were 3,460 and
2,713 in 2 different sections of MACS2 frontal lobe, 21,683 in
MACS2 lymph node, 6,129 in MACS2 spleen, 1,645 in
MACS3 frontal lobe and 252,104 in MACS3 lymph node. The
HIV-1 nef gene was amplified by nested PCR performed on 1 μl
131K. Agopian et al. / Virology 358 (2007) 119–135of undiluted genomic DNA (bulk PCR) or at limiting dilution.
Dilutions were determined to be limiting when an average of 3 of
10 PCR reactions were positive. For brain genomic DNA,
limiting dilutions ranged from 1:2 to 1:8. For lymph node and
spleen DNA, dilutions ranged from 1:50 to 1:200. Maximally
conserved primer binding sites were selected. To reduce effects
of selective amplification, 2 different sets of nested PCR primers
were used. Positions of the primer sequences in the HIV-1 HXB2
genome are given in parentheses. For the first set, outer primers
were Nef1 (5′-GCCCGAAGGAATAGAAGAAG-3′) (8411–
8430) and Nef2 (5′-GCACTCAAGGCAAGCTTTATT-
GAGGC-3′) (9631–9605). The Nef2 primer was previously
published (Huang et al., 1995). Inner primers included the
restriction sites BamHI and ClaI (underlined) and were Nef3b.5
(5′-TTAGTGAACGGATCCTTAGCACTTATCTGGG-3′)
(8466–8496) and Nef4.5 (5′-GCGGAAAGTCCCTTGTAG-
CAACATCGATGTCA-3′) (9446–9415). For the second set,
outer primers were Nef5′b (5′-GCAGTAGCTGAGGGGACA-
GATAGGGTTATAG) (8685–8705) and Nef2. Inner primers
were HI5′ (5′-CGTCTAGAACATACCTAGAAGAATAAGA-
CAGG) (8748–8768) and NFkB3′ (5′-AAAGTCCCCAGCG-
GAAAGTCCC) (9456–9435). All reactions were performed
with Pfu polymerase (Stratagene). The HI5′ primer was
previously published (Huang et al., 1995).The cycling condi-
tions for the 50 μl first-round reaction were 94 °C (2 min),
followed by 30 cycles of 94° (15 s), 57 °C (15 s), 68 °C (3 min),
and then the final elongation step at 72 °C (7 min). 1 μl of the
first-round PCR product was used as template for the second-
round reaction. The cycling conditions for the second-round
primer set were the same except that hybridization was
performed at 55 °C. PCR products were purified using the
Qiaquick PCR purification kit and were either sequenced
directly (represented by numbers, e.g. LN-15) or cloned into
the pCR3.1 expression vector and sequenced (represented by
numbers and letters, e.g. LN-15A). From each tissue, 11 to 34
independent sequences were obtained.
The nucleotide and amino acid sequences from MACS2
frontal lobe (DQ885391–DQ885408), MACS2 lymph node
(DQ358015–DQ358036), MACS2 spleen (DQ358037–
DQ358047), MACS3 frontal lobe (DQ885409–DQ885420),
and MACS3 lymph node (DQ885421–DQ885454) have been
submitted to the GenBank sequence database.
Amplification of HIV-1 Nef alleles from viral isolates
The primary HIV-1 viruses MACS2-LN, MACS3-br and
MACS3-LN were isolated from patients MACS2 and MACS3
and characterized as described (Gorry et al., 2001). Briefly,
autopsy lymph node and brain tissue samples were homo-
genized and cocultured with CD8-depleted PBMC. Super-
natants testing positive for reverse transcriptase activity were
filtered and stored at −80 °C. From cell pellets of cultured
PBMC infected with viral supernatants, DNA was extracted
using a Qiagen DNeasy kit. Nef alleles were amplified and
cloned from 1 μl undiluted genomic DNA as described above.
The nucleotide and amino acid Nef sequences of viral isolate-
derived clones MACS2LN-5C (DQ357219), MACS2LN-5F(DQ358012), MACS2LN-5G (DQ358013), MACS2LN-5H
(DQ358014), MACS3br-6I (DQ357220), and MACS3LN-7D
(DQ357221) have been submitted to GenBank.
Phylogenetic analysis
Sequences from each independent limiting dilution PCR
reaction and each clone from bulk PCR were included in the
phylogenetic analyses. Alignments were made using Clustal W.
Bootstrapped phylogenetic trees were created by the neighbor-
joining method using Clustal X.
Plasmids and mutagenesis
The NL4-3 nef allele was amplified from the pNL4-3
proviral plasmid by PCR with primers Nef3b.5 and Nef 4.5 and
inserted into pCR3.1 by TA cloning. The SF2 nef allele was
cloned into the EcoRI site of vector PCDNA3.1 (Foster et al.,
2001). The pCR3.1 vector lacking an insert was used for mock
transfections. Mutations were created using the QuikChange
site-directed mutagenesis kit (Stratagene) and all mutants were
confirmed by sequencing.
Cell culture
293T cells and HIJ cells (HeLa cells retrovirally transduced
to express high levels of CD4), provided by David Kabat (Kabat
et al., 1994), were maintained in Dulbecco's modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum
and 100 μg/ml penicillin/streptomycin. Jurkat-T-Antigen (J-
TAg) cells (Northrop et al., 1993), provided by Heinrich
Gottlinger, were maintained in RPMI 1640 supplemented with
10% fetal bovine serum and 100 μg/ml penicillin/streptomycin.
CD4 and MHC-I downregulation assays
For CD4 downregulation assays, HIJ cells were co-
transfected with nef and pCDNA3-EGFP expression plasmids
using Lipofectamine 2000 (Invitrogen). Cells were harvested
after 28 h and stained for 30 min at 4 °C with saturating amounts
of PE-conjugated mouse anti-CD4 antibody (BD Pharmingen).
Stained cells were analyzed by flow cytometry and dead cells
were excluded by forward and side scatter (Becton Dickinson
FACScan). The geometric mean of CD4-PE fluorescence
intensity was calculated for transfected (GFPpos) and untrans-
fected (GFPneg) cell populations. To calculate the relative mean
fluorescence intensity (relMFI) of each transfected sample, the
following formula was used: relMFIsample= ((MFIGFPpos) /
(MFIGFPneg)sample) / ((MFIGFPpos) / (MFIGFPneg)Vector). This for-
mula corrects for slight staining variation between stained
samples and expresses the CD4 surface levels relative to the
mock-transfected negative control.
MHC-I downregulation assays were performed by co-
transfecting Jurkat T-Antigen cells with nef and pCDNA3-
EGFP plasmids using Lipofectamine 2000. Cells were activated
4 h later with 1 μg/ml PHA-L and 50 ng/ml PMA. Cells were
harvested after 28 h and stained with a saturating amount of PE-
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Stained cells were analyzed by flow cytometry as described
above. The relative MFI of HLA-ABC-PE fluorescence was
calculated for high-GFP-expressing (GFPhigh) using the
formula described above.
Western blots
Aliquots of cells used for CD4 and MHC-I downregulation
assays were lysed in Cold Lysis Buffer (50 mMTris HCl pH 7.5,
150 mM NaCl, 10% glycerol, 1% Triton X-100, Complete
protease inhibitors (Roche)). Lysates were centrifuged at
14,000 rpm for 20 min at 4 °C to remove cell debris. Equal
amounts of total protein were run on 12% SDS-PAGE gels and
analyzed by Western blotting with rabbit anti-Nef #2949 (AIDS
Research and Reference Reagent Program), rabbit anti-Nef Bru
#188 (Zazopoulos and Haseltine, 1992), or sheep anti-Nef SF2
(Foster et al., 2001). Aliquots of cell lysates used for the IVKAs
were tested for Nef expression by Western blot with sheep
polyclonal anti-Nef SF2 serum (1:2000 dilution) as described
(Foster et al., 2001) or rabbit anti-Nef #2949 (1:2000 dilution).
In vitro kinase assays (IVKAs)
IVKAs were performed as previously described (Foster et al.,
2001). Briefly, 293T cells transfected (Lipofectamine 2000,
Invitrogen) with Nef and pN1GFP plasmids were lysed in IVKA
Lysis Buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10% glycerol,
0.5% IGEPAL CA-630) (Sigma), 1 mM EDTA, 25 mM NaF,
2 mM Na3VO4, 20 mM beta-glycerophosphate, 1 mM PMSF,
25 mM benzamidine and Complete protease inhibitors (Roche).
Cleared whole cell lysates (600 μg) were immunoprecipitated
with sheep-anti-Nef serum. Kinase reactions were performed on
immunoprecipitates in the presence of [γ32P] ATP and separated
by 10% SDS-PAGE gels. Dried gels were exposed to a
phosphoimager screen (Packard).
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